AMERIPATH
ANNOUNCES ADVANCED TESTING FOR MYELOPROLIFERATIVE
DISORDERS
Palm Beach Gardens, FL, March 29, 2006
AmeriPath,
Inc., a leading national provider of physician-based anatomic pathology, has developed
a new assay that detects and quantifies a mutation in the Janus kinase 2 (JAK2) gene common in bcr/ablnegative myeloproliferative disorders (MPDs). The JAK2 V167F Mutation
Analysis, available through both AmeriPath and Specialty Laboratories,
can aid in or confirm the diagnosis of polycythemia vera, essential thrombocythemia, or idiopathic myelofibrosis, thereby giving physicians a dynamic new diagnostic tool to
more effectively manage
treatment decisions for improved patient outcomes.
With its maximized specificity and sensitivity, this new assay offers physicians the
following:
• Potentially earlier and more confident diagnosis
of bcr/abl-negative MPD patients
• Rapid, real-time PCR analysis for earlier implementation
of appropriate treatment
• A quantitative result that provides a reference point for
future patient assessments
“
We’re very excited about how this test can improve
the assessment of myeloproliferative disorders,” said Russell L.
Maiese, M.D., National Director of Hematopathology, AmeriPath, Inc. “It’s an outstanding development for AmeriPath, but more importantly, it’s a valuable one for our physicians and their patients.”
 |
About AmeriPath, Inc.
AmeriPath, a leading national provider of physician-based
anatomic pathology,
dermatopathology and molecular diagnostic services to
physicians, hospitals, clinical
laboratories and surgery centers, supports community-based
medicine by helping
physicians provide excellent and effective care for their
patients. A team of subspecialized
pathologists and Ph.D. scientists provide medical expertise,
diagnostic
quality, and personal consultation services. AmeriPath’s
team of more than 400 highly
trained, board-certified pathologists and Ph.D.-level
scientists provide medical
diagnostics services in outpatient laboratories owned,
operated and managed by
AmeriPath, as well as in hospitals and ambulatory surgical
centers.
About Specialty Laboratories, Inc.
Specialty Laboratories supports local pathology and community-based
medicine by
partnering with pathologists and hospitals to improve patient
care and reduce episodesof-
care costs. Specialty offers hospitals an extensive menu
of highly advanced clinical
tests used by physicians to diagnose, monitor, and treat
disease and a single-source
solution for esoteric testing needs. Specialty’s Web
address is www.specialtylabs.com.
Media Contact:
Kelly Shaw
Kelly@redhouseusa.com
(770)475-2103
Interview Opportunity:
Russell L. Maiese, M.D.
National Director of Hematopathology
AmeriPath, Inc.
